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This is a randomized, double blind, placebo controlled, parallel group multicenter study 
in women with biopsy confirmed Grade 2 or Grade 3 cervical intraepithelial neoplasia 
(CIN). Two hundred patients will be enrolled and randomized in a 2: 1 ratio of 
RO5217790: placebo. They will be stratified on the basis of their HPV genotyping with 
stratum 1 consisting of those women with HPV 16 single infection and stratum 2 
consisting of those with single or multiple infections with other high risk genotypes. 
Three injections of RO5217790 (5 x 107pfu) will be administered subcutaneously, each 
one week apart. Interim colposcopy, cytology and HPV assessments will be performed 
at Month 3. All patients will undergo conization at Month 6. The primary endpoint is 
histologic response at Month 6 in HPV 16 single infected patients, as assessed by 
central pathology review. The secondary endpoints include histologic response in all 
CIN2/3 patients enrolled regardless of genotype, viral clearance, safety, and immune 
response (cellular and humoral). After the Month 6 conization, the study will be 
unblinded and patients will undergo follow-up for an additional 2 years for efficacy and 
safety. This includes visits at Months 12, 18, 24 and 30 to assess histologic 
relapse/recurrence and viral re-infection as well as reporting of any serious adverse 
events. An interim analysis will be conducted when a minimum of 80 patients (at least 
20 of whom have single infection with HPV 16 and 20 of whom have infection with HPV 
16 plus HPV 16 related genotypes) have undergone conization. 
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